Navigation Links
TheraQuest's IND for Abuse Deterrent Strong Opioid (TQ-1015) Accepted by FDA
Date:11/12/2008

BLUE BELL, Pa., Nov. 13 /PRNewswire/ -- TheraQuest Biosciences, Inc. a development stage pain management company today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug ("IND") application for TQ-1015, its abuse deterrent extended release strong opioid. TQ-1015 is being developed using SECUREL(R), TheraQuest's proprietary abuse deterrent technology.

Najib Babul, PharmD, Chief Executive Officer of TheraQuest stated, "Sustained release opioids are the standard of care for the management of chronic pain. Unfortunately, it is easy to defeat the sustained release mechanim of such dosage forms, making them subject to drug diversion and drug abuse. The TQ-1015 dosage form is highly tamper resistant, when compared to OxyContin(R), thereby minimizing abuse by recreational drug users and drug addicts."

About TQ-1015

TQ-1015 is a once-a-day extended release opioid analgesic for the treatment of chronic pain. It has been developed using TheraQuest's proprietary abuse deterrent extended release drug delivery system (SECUREL(R)). TQ-1015 is significantly more potent than many current oral therapies, including morphine and oxycodone. It shows robust efficacy in various animal models of acute pain, inflammatory pain and neuropathic pain. TQ-1015 will compete in the $8.3 billion U.S. opioid market.

About SECUREL(R)

Recent experience with extended release opioid pain relievers has shown that intentional crushing or extraction of the active ingredient from the dosage form by addicts and recreational drug users can destroy the timed-release mechanism and result in a rapid surge of drug into the bloodstream. Serious side-effects and death have been reported from such misuse.

SECUREL(R) is TheraQuest's proprietary abuse deterrent extended release technology for oral abusable drugs. SECUREL(R) dosage forms cannot be easily crushed for inhalation or to obtain rapid euphoria from high blood levels when swallowed. It is also exceedingly difficult for I.V. abusers to extract the active drug from the dosage form using common solvents, including alcohol.

About TheraQuest

TheraQuest Biosciences, Inc. (http://www.theraquestinc.com) is a private, development-stage pain management company building a diversified portfolio of pharmaceutical products to address a critical area of unmet medical need. Despite their limitations, current treatments for acute and chronic pain yield worldwide sales in excess of $30 billion. The TheraQuest team has contributed to the development of numerous analgesics approved in the U.S. over the past 20 years. TheraQuest's strategy is to use its expertise to identify, develop and commercialize product candidates with strong market potential that have lower development costs and reduced regulatory risk than new chemical entities. TheraQuest is headquartered in Blue Bell, Pennsylvania.

TheraQuest is funded in part by BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania and Ben Franklin Technology Partners of Southeastern Pennsylvania.

SECUREL(R) and OxyContin(R) are registered trademarks of TheraQuest Biosciences, Inc., and Purdue Pharma LP., respectively.


'/>"/>
SOURCE TheraQuest Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Disability payments may spur drug abuse
2. Leading Child Abuse Center Releases Back to School Tips to Protect Children From Internet Predators
3. Inhalant Abuse Prevention Program to Be Launched in Maryland Schools
4. Research examines connection between substance abuse and violence
5. Steroids Are Abused for Skin, Not Just Muscles
6. L.A. Author, TV Personality and Substance Abuse Specialist Discusses Struggle to Break Bad-girl Syndrome Oct. 26-28 in Baltimore
7. Dealing with stress as a treatment for alcohol abuse
8. Culture can Affect Access to Alcohol, Drug Abuse Treatment for Rural Youth
9. King Pharmaceuticals and Acura Pharmaceuticals Enter Agreement to Develop and Commercialize Immediate Release Pain Medicines Utilizing Acuras Aversion(R) (Abuse-Deterrent) Technology
10. CHPA Commends Senator Biden on Legislation Aimed at Curbing Medicine-Abuse Trend
11. Substance abuse practitioners ask what is recovery?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for professional women, ... towards gender equality at their inaugural Summit in New York City in June. The ... social audience of over 3 million. To watch the Mobilize Women video, click ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, a ... has been awarded a contract by the Center for Medicare and Medicaid Services ... accelerate the enterprise use of Agile methodologies in a consistent and high value ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the ... published author, William Nowers. Captain Nowers and his wife, Millie, have six children, ... in the Navy. Following his career as a naval aviator and carrier pilot, ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
Breaking Medicine News(10 mins):
(Date:10/10/2017)... , Oct. 10, 2017  NDS received FDA 510(k) clearance in ... medical-grade battery-powered display stand specifically designed for endoscopy environments. An innovative ... into a clinical solution to support the improvement of patient outcomes, ... Design ... Solution ...
(Date:10/7/2017)... 6, 2017   Provista, a proven leader ... billion in purchasing power, today announced a new resource ... The Newsroom is the online home for case ... expert bios, news releases, slideshows and events. ... wealth of resources at their fingertips, viewers can also ...
(Date:10/4/2017)... SEOUL, South Korea , Oct. 4, 2017 /PRNewswire/ ... launched its next-generation CPR training aide "cprCUBE" on Kickstarter. ... of chest compression during cardiac arrests with better efficiency ... patient-mannequins. It also offers real-time feedback on efficacy of ... The crowdfunding campaign has a goal to raise ...
Breaking Medicine Technology: